Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLRB Cellectar Biosciences	$4.51 +0.1%	$6.28	$4.11 ▼ $68.70	$8.15M	0.42	225,419 shs	122,662 shs
ENLV Enlivex Therapeutics	$1.12 +6.2%	$1.25	$0.81 ▼ $2.10	$26.37M	0.8	247,969 shs	833,054 shs
KPTI Karyopharm Therapeutics	$6.52 +4.8%	$4.42	$3.51 ▼ $16.95	$56.53M	0.28	127,704 shs	303,240 shs
SCYX SCYNEXIS	$0.80 +1.3%	$0.75	$0.66 ▼ $1.79	$33.54M	1.64	169,315 shs	91,660 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLRB Cellectar Biosciences	-4.26%	-2.39%	-9.82%	-39.76%	-92.68%
ENLV Enlivex Therapeutics	-16.00%	-33.12%	-11.76%	+7.20%	-16.67%
KPTI Karyopharm Therapeutics	+11.27%	+54.73%	+61.56%	+32.34%	-49.07%
SCYX SCYNEXIS	-1.56%	-8.13%	+8.97%	+2.49%	-54.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLRB Cellectar Biosciences	2.4035 of 5 stars	3.3	2.0	0.0	2.9	1.7	0.6
ENLV Enlivex Therapeutics	3.3267 of 5 stars	3.7	5.0	0.0	2.9	0.8	0.6
KPTI Karyopharm Therapeutics	3.8655 of 5 stars	3.4	0.0	4.6	2.4	2.5	0.6
SCYX SCYNEXIS	1.3708 of 5 stars	0.0	5.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLRB Cellectar Biosciences	2.50	Moderate Buy	$375.00	8,224.08% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	796.86% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$34.00	421.47% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLRB, KPTI, ENLV, and SCYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/14/2025	CLRB Cellectar Biosciences	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$42.00 ➝ $25.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	$3.07 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.39	N/A	N/A	($27.55) per share	-0.24
SCYX SCYNEXIS	$3.75M	8.94	N/A	N/A	$1.06 per share	0.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLRB Cellectar Biosciences	-$44.58M	-$19.91	N/A	N/A	N/A	N/A	-486.67%	-150.57%	N/A
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)
SCYX SCYNEXIS	-$21.29M	-$0.40	N/A	16.00	N/A	-599.05%	-43.04%	-28.21%	11/5/2025 (Estimated)

Latest CLRB, KPTI, ENLV, and SCYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	CLRB Cellectar Biosciences	-$3.60	-$3.39	+$0.21	-$3.39	N/A	N/A
8/13/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	-$0.14	+$0.09	-$0.14	$0.15 million	$1.36 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLRB Cellectar Biosciences	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLRB Cellectar Biosciences	N/A	2.15	2.47
ENLV Enlivex Therapeutics	N/A	7.20	7.20
KPTI Karyopharm Therapeutics	N/A	0.99	0.94
SCYX SCYNEXIS	N/A	5.20	5.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLRB Cellectar Biosciences	16.41%
ENLV Enlivex Therapeutics	1.02%
KPTI Karyopharm Therapeutics	66.44%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
CLRB Cellectar Biosciences	5.04%
ENLV Enlivex Therapeutics	12.28%
KPTI Karyopharm Therapeutics	2.75%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLRB Cellectar Biosciences	10	1.81 million	1.72 million	Optionable
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.43 million	Optionable
SCYX SCYNEXIS	60	41.92 million	39.89 million	Optionable

CLRB, KPTI, ENLV, and SCYX Headlines

Recent News About These Companies

Scynexis reports Q2 EPS (14c), consensus (19c)

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | finanznachrichten.de

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

August 14, 2025 | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13, 2025 | globenewswire.com

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

August 13, 2025 | americanbankingnews.com

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

August 8, 2025 | msn.com

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB, KPTI, ENLV, and SCYX Company Descriptions

Cellectar Biosciences NASDAQ:CLRB

$4.50 +0.01 (+0.11%)

Closing price 03:59 PM Eastern

Extended Trading

$4.43 -0.07 (-1.55%)

As of 04:10 PM Eastern

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Enlivex Therapeutics NASDAQ:ENLV

$1.12 +0.07 (+6.19%)

Closing price 03:58 PM Eastern

Extended Trading

$1.10 -0.01 (-0.99%)

As of 04:11 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Karyopharm Therapeutics NASDAQ:KPTI

$6.52 +0.30 (+4.82%)

Closing price 03:58 PM Eastern

Extended Trading

$6.46 -0.05 (-0.84%)

As of 04:11 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

SCYNEXIS NASDAQ:SCYX

$0.80 +0.01 (+1.27%)

Closing price 03:58 PM Eastern

Extended Trading

$0.81 +0.01 (+1.25%)

As of 04:10 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time